Aberrant antigen expression in marrow specimens from 49 patients with precursor B-ALL
| . | No. of patients . |
|---|---|
| Aberrant expression of antigens found on normal B-cell precursors | |
| TdT | |
| Uniform expression | 26/30 (87%) |
| CD34 | |
| Uniform or continuous spectrum of expression | 30/35 (86%) |
| CD45 | |
| Negative or underexpression | 40/48 (83%) |
| CD10 | 40/49 (82%) |
| Overexpression | 28 (57%) |
| Abnormal spectrum | 7 (14%) |
| Negative | 5 (10%) |
| CD20 | 17/35 (49%) |
| Negative | 16 (46%) |
| Overexpression | 1 (3%) |
| HLA-DR | 22/47 (47%) |
| Underexpression | 21 (45%) |
| Overexpression | 1 (2%) |
| CD22 | 14/34 (41%) |
| Abnormal spectrum | 12 (35%) |
| Negative | 2 (6%) |
| Coexpression of CD34 and CD20 | 14/34 (41%) |
| CD38 | |
| Underexpression | 13/32 (41%) |
| CD19 | |
| Underexpression | 9/49 (18%) |
| Aberrant myeloid antigen expression | |
| All cases | 28/485-150 (58%) |
| Cases in which 5 or more myeloid antigens were assessed | 25/32 (78%) |
| Single aberrant myeloid antigen | 8 (25%) |
| Two aberrant myeloid antigens | 10 (31%) |
| Three aberrant myeloid antigens | 7 (22%) |
| Frequency of aberrant expression of myeloid antigens | |
| CD13 | 15/32 (47%) |
| CD15 | 13/33 (39%) |
| CD33 | 16/47 (34%) |
| CD11b | 4/32 (13%) |
| CD36 | 2/32 (6%) |
| CD64 | 2/32 (6%) |
| CD14 | 0/34 |
| CD61 | 0/30 |
| MPO | 0/26 |
| Aberrant T-cell antigen expression | |
| CD7 | 3/45 (7%) |
| CD3 | 0/48 |
| IcCD3 | 0/31 |
| CD5 | 0/48 |
| CD8 | 0/33 |
| CD4 | 0/33 |
| CD1a | 0/26 |
| . | No. of patients . |
|---|---|
| Aberrant expression of antigens found on normal B-cell precursors | |
| TdT | |
| Uniform expression | 26/30 (87%) |
| CD34 | |
| Uniform or continuous spectrum of expression | 30/35 (86%) |
| CD45 | |
| Negative or underexpression | 40/48 (83%) |
| CD10 | 40/49 (82%) |
| Overexpression | 28 (57%) |
| Abnormal spectrum | 7 (14%) |
| Negative | 5 (10%) |
| CD20 | 17/35 (49%) |
| Negative | 16 (46%) |
| Overexpression | 1 (3%) |
| HLA-DR | 22/47 (47%) |
| Underexpression | 21 (45%) |
| Overexpression | 1 (2%) |
| CD22 | 14/34 (41%) |
| Abnormal spectrum | 12 (35%) |
| Negative | 2 (6%) |
| Coexpression of CD34 and CD20 | 14/34 (41%) |
| CD38 | |
| Underexpression | 13/32 (41%) |
| CD19 | |
| Underexpression | 9/49 (18%) |
| Aberrant myeloid antigen expression | |
| All cases | 28/485-150 (58%) |
| Cases in which 5 or more myeloid antigens were assessed | 25/32 (78%) |
| Single aberrant myeloid antigen | 8 (25%) |
| Two aberrant myeloid antigens | 10 (31%) |
| Three aberrant myeloid antigens | 7 (22%) |
| Frequency of aberrant expression of myeloid antigens | |
| CD13 | 15/32 (47%) |
| CD15 | 13/33 (39%) |
| CD33 | 16/47 (34%) |
| CD11b | 4/32 (13%) |
| CD36 | 2/32 (6%) |
| CD64 | 2/32 (6%) |
| CD14 | 0/34 |
| CD61 | 0/30 |
| MPO | 0/26 |
| Aberrant T-cell antigen expression | |
| CD7 | 3/45 (7%) |
| CD3 | 0/48 |
| IcCD3 | 0/31 |
| CD5 | 0/48 |
| CD8 | 0/33 |
| CD4 | 0/33 |
| CD1a | 0/26 |
MPO indicates myeloperoxidase; IcCD3, intracellular (cytoplasmic) CD3.
The bone marrow from 1 of the 49 patients with ALL was not assessed for myeloid antigens.